Phibro Animal Health vs Prestige Consumer Healthcare
PAHC and PBH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PAHC and PBH compare
Prestige Consumer Healthcare is the larger company, worth 1.5 times as much as Phibro Animal Health ($2.3B against $1.6B).
On earnings, Prestige Consumer Healthcare is cheaper: it trades at 13.7× trailing earnings, against 16.0× for Phibro Animal Health.
Phibro Animal Health grew revenue faster over the last twelve months (17.1% versus −1.4% for Prestige Consumer Healthcare).
Prestige Consumer Healthcare keeps more of each dollar of sales as profit, with a net margin of 15.6% compared with 6.6% at Phibro Animal Health.
Phibro Animal Health pays a dividend yielding 1.2%; Prestige Consumer Healthcare does not pay one.
Phibro Animal Health scores higher on the StockData Score (22 against 12 for Prestige Consumer Healthcare), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PAHC | PBH |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | $2.3B |
| Share price | $38.88 | $49.06 |
| Change, 1 year | −5.6% | −19.2% |
| Change, 5 years | 73.8% | −22.0% |
| Beta (5Y) | 0.73 | 0.40 |
| Employees | 2,605 | 890 |
| StockData Score | ||
| Total score | 22 (better) | 12 |
| Valuation score | 5 | 5 |
| Growth score | 6 (better) | 1 |
| Performance score | 6 (better) | 4 |
| Health score | 2 | 2 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 16.0× | 13.7× (better) |
| P/S | 1.0× (better) | 2.1× |
| P/B | 4.1× | 1.2× (better) |
| EV/EBITDA | 6.1× (better) | 13.2× |
| P/FCF | 160× | 9.9× (better) |
| PEG | 0.36 | – |
| FCF yield | 0.62% | 10.1% (better) |
| Fair value | $64.80 | $65.02 |
| Margin of safety | 40.0% (better) | 24.6% |
| Growth | ||
| Revenue growth (TTM) | 17.1% (better) | −1.4% |
| Revenue growth, 5Y average | 12.7% (better) | 2.9% |
| Net income growth (TTM) | 107% (better) | −19.2% |
| EPS growth (TTM) | 104% (better) | −16.2% |
| EPS growth, 5Y average | 12.6% (better) | 3.8% |
| Profitability | ||
| Gross margin | 33.8% | 53.5% (better) |
| Operating margin | 12.8% | 26.3% (better) |
| Net margin | 6.6% | 15.6% (better) |
| FCF margin | 0.65% | 21.3% (better) |
| Return on equity | 29.7% (better) | 9.1% |
| Return on invested capital | 24.7% (better) | 8.2% |
| Financial health | ||
| Debt / equity | – | 1.05 |
| Net debt / EBITDA | – | 5.98 |
| Interest coverage | 4.2× | – |
| Current ratio | 2.96 | 3.23 (better) |
| Altman Z-score | 3.11 (better) | 1.61 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 1.2% | – |
| Payout ratio | 19.5% | – |
| Years of dividend growth | 0 | – |
| Dividend growth, 5Y average | 0.00% | – |
| Buyback yield | – | 5.2% |
| Shareholder yield | 1.2% | 5.2% (better) |
| Ownership | ||
| Held by institutions | 51.8% | 113% |
| Held by insiders | 98.9% | 1.4% |
| Insider net buying, 12 months | −$27.8M | −$424K (better) |
| Short interest, % of float | 234% | 9.9% |
Go deeper
- PAHC stock overview
- PAHC income statement
- PAHC valuation and score
- PBH stock overview
- PBH income statement
- PBH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.